Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [5].

Core Viewpoint - A class action securities lawsuit has been filed against James Hardie Industries plc, alleging securities fraud that negatively impacted investors between May 20, 2025, and August 18, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud during the specified period [2]. - The complaint claims that the defendants made false statements and concealed adverse facts regarding the North America segment of James Hardie, including deteriorating consumer demand and excessive inventory at distributors [3]. Group 2: Investor Information - Investors who suffered losses during the relevant timeframe have until December 23, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr misled investors regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage completely [2] - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a significant stock price drop of 83.2% from $6.03 to $1.02 per share in one day [2] Case Details - The lawsuit seeks to recover losses for investors who were adversely affected by the alleged fraud [1] - The primary endpoint that was not met involved the change from baseline in mean daily OSC dose at week 48 [2] - Following the disappointing results, aTyr plans to engage with the FDA to determine the next steps [2] Next Steps - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no costs or obligations for class members [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - WPP plc is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 27, 2025, and July 8, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that WPP's management made overly positive statements while concealing material adverse facts about the company's media arm, which was struggling to compete effectively amid macroeconomic challenges [2] - On July 9, 2025, WPP reported a deterioration in performance for Q2 2025, attributing this to macroeconomic uncertainty and weaker new business, compounded by ongoing restructuring within WPP Media [2] - Following the trading update, WPP's stock price plummeted from $35.82 per share on July 8, 2025, to $29.34 per share on July 9, 2025, marking an approximate decline of 18.1% in one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A class action securities lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud affecting investors between February 26, 2025, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed information regarding the company's revenue outlook and growth potential, particularly related to Pylarify's market dynamics [2]. - It is alleged that Lantheus' optimistic reports on Pylarify's sales growth and pricing normalization did not reflect the actual market conditions, indicating a lack of accurate understanding of competitive dynamics [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, ensuring no financial obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to client service [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Coty, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Financial Performance - Coty disclosed its financial results for the full fiscal year of 2025 and its fourth quarter in a Current Report on Form 8-K filed on August 20, 2025 [3]. - The Chief Financial Officer of Coty attributed sluggish sales to several factors, including value-seeking behavior, innovation fatigue among consumers, and changes in anti-theft and immigration policies [3]. Group 2: Stock Market Reaction - Following the news of Coty's financial performance, the company's stock price fell by $1.05 per share, representing a decline of 21.6%, closing at $3.81 per share on August 21, 2025 [4]. Group 3: Legal Action and Investor Rights - Investors who purchased Coty securities may be entitled to compensation through a class action lawsuit being prepared by Rosen Law Firm, which operates on a contingency fee basis [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [5].

Core Points - Rosen Law Firm is reminding investors about a class action lawsuit filed on behalf of Savara Inc. (NASDAQ: SVRA) shareholders for the period between March 7, 2024, and May 23, 2025 [1][4] - The lawsuit alleges that Savara misled investors regarding its business operations, particularly concerning the Biologics License Application (BLA) for MOLBREEVI, a treatment for a rare lung disease [2][3] Allegations - The lawsuit claims that Savara's BLA for MOLBREEVI lacked sufficient information on its chemistry, manufacturing, and controls, making FDA approval unlikely in its current form [3] - It is alleged that Savara would not complete the BLA submission within the previously represented timeframe, increasing the likelihood of needing additional capital [3] - The public statements made by Savara were claimed to be materially false and misleading, resulting in investor damages when the true details emerged [3] Legal Proceedings - Investors interested in serving as lead plaintiffs must file motions with the court by November 7, 2025 [4] - Participation in the case is not required to be eligible for recovery, allowing investors to remain absent class members if they choose [4] Rosen Law Firm Overview - Rosen Law Firm specializes in shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6]

Core Viewpoint - WPP plc is facing a class action lawsuit due to allegations of providing misleading statements about its media arm's performance, leading to a significant drop in stock price after a disappointing trading update [1]. Summary by Sections Allegations - The complaint claims that WPP's management made overly positive statements while concealing adverse facts about the company's ability to handle macroeconomic challenges and competition, resulting in a loss of market share [1]. - On July 9, 2025, WPP reported a deterioration in performance for Q2 2025, attributing it to macroeconomic uncertainties and weaker new business, partly due to ongoing restructuring within WPP Media (GroupM) [1]. Stock Price Impact - Following the trading update on July 9, 2025, WPP's stock price plummeted from $35.82 per share to $29.34 per share, marking an approximate decline of 18.1% in just one day [1]. Class Action Details - Shareholders who purchased WPP shares during the class period from February 27, 2025, to July 8, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 8, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Fortinet, Inc. regarding a class action lawsuit due to alleged false statements and misrepresentations made by the company during a specific class period [1]. Group 1: Allegations and Class Period - The class period for the alleged misconduct is from November 8, 2024, to August 6, 2025 [1]. - Allegations include that Fortinet misrepresented the potential profitability of a product refresh cycle, claiming it would be more lucrative than it actually was, as it involved old products that constituted a "small percentage" of the company's business [1]. - The complaint also states that Fortinet did not have a clear understanding of the number of FortiGate firewalls eligible for upgrades and misled investors about the momentum of the refresh cycle, which was pushed through aggressively in a short time frame [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of FTNT during the specified period are encouraged to register for the class action, with a deadline for lead plaintiff applications set for November 21, 2025 [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Alector, Inc. following disappointing clinical trial results for its drug, latozinemab, which did not meet primary endpoints [1][2]. Group 1: Company Overview - Alector, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases [2]. - The company recently announced results from the Phase 3 INFRONT-3 clinical trial for latozinemab, which targets frontotemporal dementia due to a progranulin gene mutation [2]. Group 2: Clinical Trial Results - The Phase 3 clinical trial results indicated that latozinemab failed to meet its clinical co-primary endpoint of slowing the progression of frontotemporal dementia [2]. - Secondary and exploratory endpoints, including fluid biomarkers and volumetric magnetic resonance imaging (vMRI), showed no treatment-related effects [2]. Group 3: Market Reaction - Following the announcement of the trial results, Alector's stock price dropped by $1.60 per share, representing a decline of 49.84%, closing at $1.61 per share on October 22, 2025 [2].